Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

기사 요약

Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.